İsmail Eralp Kaçmaz1, Burçin Keçeci2, Can Doruk Basa1, Dündar Sabah2. 1. Department of Orthopaedics and Traumatology, Tepecik Training and Research Hospital, İzmir, Turkey. 2. Department of Orthopaedics and Traumatology, Ege University, School of Medicine, İzmir, Turkey.
Abstract
OBJECTIVE: The aim of this study was to compare the results of chemotherapy or combined chemotherapy-radiation therapy with surgical intervention following neodjuvant therapy in pelvic Ewing's sarcoma patients. METHODS: The study population consisted of 39 patients with pelvic Ewing's sarcoma treated in our clinic between 1994 and 2014. Of these patients, 28 patients (11 boys and 17 girls; mean age: 19.57±6.8 years) were treated with chemotherapy and radiation therapy and the remaining 11 patients (9 boys and 2 girls; mean age: 18.64±8.1 years) patients underwent surgical intervention after neoadjuvant chemotherapy or chemotherapy plus radiation therapy. Internal hemipelvectomy was performed in 10 patients, and external hemipelvectomy was performed in one patient. Survival rates were compared between the surgical and non-surgical treatment groups. Predictive factors, such as treatment protocol (surgery, neoadjuvant chemotherapy, definitive radiotherapy), mass localisation, mass size, presence of metastasis at the time of diagnosis, and presence of late metastases were compared between the groups. The effects of each variable on survival were also examined. RESULTS: The overall 3- and 5-year survival rates of the 28 non-surgical patients were 41.4% and 26.1%, respectively, while those of the surgical patients were 53% and 35.4%, respectively (p=0.777). Large mass size, presence of metastasis at the time of diagnosis, and presence of late metastases were significantly associated with lower survival rates. CONCLUSION: The survival rates of the patients who underwent surgery were higher than those of non-surgical patients, although the difference was not statistically significant. Definitive radiation and chemotherapy would be preferable in selected cases, such as patients with sacral localisation, without surgical intervention. LEVEL OF EVIDENCE: Level III, Therapeutic Study.
OBJECTIVE: The aim of this study was to compare the results of chemotherapy or combined chemotherapy-radiation therapy with surgical intervention following neodjuvant therapy in pelvic Ewing's sarcomapatients. METHODS: The study population consisted of 39 patients with pelvic Ewing's sarcoma treated in our clinic between 1994 and 2014. Of these patients, 28 patients (11 boys and 17 girls; mean age: 19.57±6.8 years) were treated with chemotherapy and radiation therapy and the remaining 11 patients (9 boys and 2 girls; mean age: 18.64±8.1 years) patients underwent surgical intervention after neoadjuvant chemotherapy or chemotherapy plus radiation therapy. Internal hemipelvectomy was performed in 10 patients, and external hemipelvectomy was performed in one patient. Survival rates were compared between the surgical and non-surgical treatment groups. Predictive factors, such as treatment protocol (surgery, neoadjuvant chemotherapy, definitive radiotherapy), mass localisation, mass size, presence of metastasis at the time of diagnosis, and presence of late metastases were compared between the groups. The effects of each variable on survival were also examined. RESULTS: The overall 3- and 5-year survival rates of the 28 non-surgical patients were 41.4% and 26.1%, respectively, while those of the surgical patients were 53% and 35.4%, respectively (p=0.777). Large mass size, presence of metastasis at the time of diagnosis, and presence of late metastases were significantly associated with lower survival rates. CONCLUSION: The survival rates of the patients who underwent surgery were higher than those of non-surgical patients, although the difference was not statistically significant. Definitive radiation and chemotherapy would be preferable in selected cases, such as patients with sacral localisation, without surgical intervention. LEVEL OF EVIDENCE: Level III, Therapeutic Study.
Authors: M Paulussen; S Ahrens; J Dunst; W Winkelmann; G U Exner; R Kotz; G Amann; B Dockhorn-Dworniczak; D Harms; S Müller-Weihrich; K Welte; B Kornhuber; G Janka-Schaub; U Göbel; J Treuner; P A Voûte; A Zoubek; H Gadner; H Jürgens Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Steven G DuBois; Mark D Krailo; Mark C Gebhardt; Sarah S Donaldson; Karen J Marcus; John Dormans; Robert C Shamberger; Scott Sailer; Richard W Nicholas; John H Healey; Nancy J Tarbell; R Lor Randall; Meenakshi Devidas; James S Meyer; Linda Granowetter; Richard B Womer; Mark Bernstein; Neyssa Marina; Holcombe E Grier Journal: Cancer Date: 2014-09-23 Impact factor: 6.860
Authors: Erin E Karski; Elizabeth McIlvaine; Mark R Segal; Mark Krailo; Holcombe E Grier; Linda Granowetter; Richard B Womer; Paul A Meyers; Judy Felgenhauer; Neyssa Marina; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2015-08-10 Impact factor: 3.167
Authors: Carlos Rodríguez-Galindo; Tiebin Liu; Matthew J Krasin; Jianrong Wu; Catherine A Billups; Najat C Daw; Sheri L Spunt; Bhaskar N Rao; Victor M Santana; Fariba Navid Journal: Cancer Date: 2007-07-15 Impact factor: 6.860